These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18855680)

  • 1. Carbohydrate-metal complexes and their potential as anticancer agents.
    Hartinger CG; Nazarov AA; Ashraf SM; Dyson PJ; Keppler BK
    Curr Med Chem; 2008; 15(25):2574-91. PubMed ID: 18855680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(II) complexes.
    Mikata Y; Shinohara Y; Yoneda K; Nakamura Y; Brudziñska I; Tanase T; Kitayama T; Takagi R; Okamoto T; Kinoshita I; Doe M; Orvig C; Yano S
    Bioorg Med Chem Lett; 2001 Dec; 11(23):3045-7. PubMed ID: 11714607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.
    Montaña AM; Batalla C
    Curr Med Chem; 2009; 16(18):2235-60. PubMed ID: 19519389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond platinums: gold complexes as anticancer agents.
    Nardon C; Boscutti G; Fregona D
    Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum complexes as anticancer agents.
    Kostova I
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):1-22. PubMed ID: 18221023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo.
    Ma J; Yang X; Hao W; Huang Z; Wang X; Wang PG
    Eur J Med Chem; 2017 Mar; 128():45-55. PubMed ID: 28147308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New metal complexes as potential therapeutics.
    Zhang CX; Lippard SJ
    Curr Opin Chem Biol; 2003 Aug; 7(4):481-9. PubMed ID: 12941423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Developments in the Field of Anticancer Platinum Complexes.
    Galanski MS
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):285-95. PubMed ID: 18221042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, characterization and biological investigation of platinum(ii) complexes with asparagusic acid derivatives as ligands.
    Hildebrandt J; Trautwein R; Kritsch D; Häfner N; Görls H; Dürst M; Runnebaum IB; Weigand W
    Dalton Trans; 2019 Jan; 48(3):936-944. PubMed ID: 30565617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photoswitching the cytotoxic properties of platinum(II) compounds.
    Presa A; Brissos RF; Caballero AB; Borilovic I; Korrodi-Gregório L; Pérez-Tomás R; Roubeau O; Gamez P
    Angew Chem Int Ed Engl; 2015 Apr; 54(15):4561-5. PubMed ID: 25689285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer metallotherapeutics in preclinical development.
    Kaluderović GN; Paschke R
    Curr Med Chem; 2011; 18(31):4738-52. PubMed ID: 21919843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in platinum chemotherapeutics.
    Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
    Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand.
    Zhao J; Gou S; Liu F
    Chemistry; 2014 Nov; 20(46):15216-25. PubMed ID: 25256173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
    Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
    Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent insights on the medicinal chemistry of metal-based compounds: hints for the successful drug design.
    Hernandes MZ; de S Pontes FJ; Coelho LC; Moreira DR; Pereira VR; Leite AC
    Curr Med Chem; 2010; 17(31):3739-50. PubMed ID: 20846108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving of Anticancer Activity and Solubility of Cisplatin by Methylglycine and Methyl Amine Ligands Against Human Breast Adenocarcinoma Cell Line.
    Shams Abyaneh FS; Eslami Moghadam M; Divsalar A; Ajloo D; Hosaini Sadr M
    Appl Biochem Biotechnol; 2018 Oct; 186(2):271-291. PubMed ID: 29516403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approach to accurately predict bond strength and ligand lability in platinum-based anticancer drugs.
    Ponce-Vargas M; Klein J; Hénon E
    Dalton Trans; 2020 Sep; 49(36):12632-12642. PubMed ID: 32870220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel metals and metal complexes as platforms for cancer therapy.
    Frezza M; Hindo S; Chen D; Davenport A; Schmitt S; Tomco D; Dou QP
    Curr Pharm Des; 2010 Jun; 16(16):1813-25. PubMed ID: 20337575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment.
    Zhao G; Lin H
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):137-47. PubMed ID: 15777221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.